This study is based on 194 patients with primary breast cancer treated
with adjuvant CNF combination chemotherapy, who were followed-up for
a risk of subsequent neoplasms. During an average follow-up of 4.8 yea
rs, 16 cases of new cancers were detected. Nine non-breast cancers wer
e observed versus 2.2 expected (standardized incidence ratio 4.2). Of
the patients with subsequent malignancies, 88% had received antiestrog
en (chemohormonal adjuvant therapy); the percentage among all patients
was 25%. We conclude that the benefit derived from adjuvant therapy o
f breast cancer may be reduced because of an increased risk of subsequ
ent cancers. [(C) 1998 Rapid Science Ltd.].